摘要:目的 探讨孟鲁司特钠对儿童过敏性哮喘的临床疗效.方法 筛选过敏性哮喘儿童92例,在征得患儿监护人同意的情况下采用随机双盲法分为治疗组(47例)和对照组(45例),两组患儿的基本治疗方案均相同.治疗组患儿在基础治疗上加服孟鲁司特钠咀嚼片,对照组患儿服用相同剂量的安慰咀嚼片,在治疗3个月后比较两组患者的疗效,随访6个月观察是否出现复发,同时统计患儿EOS,FEV1和PEF的相关变化情况.结果 治疗组患儿临床有效率为97.87%,与对照组比较有统计学意义(P<0.05);治疗组患儿临床体征改善情况也较对照组有所提高,差异具有统计学意义(P<0.05).两组患儿肺部功能指标均有所改善,但治疗组较对照组改善更为显著,差异具有统计学意义(P<0.05);两组患儿在治疗过程中均未发生损伤性药物不良反应,治疗组患儿复发率较对照组低.结论 孟鲁司特钠可作为儿童过敏性哮喘的辅助治疗药物,且服用安全,疗效显著.%Objective To investigate the clinical efficacy of montelukast on children with allergic asthma.Method 92 children with allergic asthma were randomly divided into the treatment group (47 cases) and control group (45 cases),the basic treatment of patients in two group were the same,treatment group of children with oral montelukast sodium chewable tablets,the control group were administered the same dose comfort chewable tablets,after 3 months of treatment,follow-up of 6 months whether relapse,related changes in children with EOS,FEV1 and statistics and PEF.Results The clinical effective rate in treatment group was 97.87%,there is statistical significance compared with the control group (P < 0.05),the treatment group in the clinical symptoms improved the situation comparing with the control group,the difference was statistically significant (P < 0.05),two groups of children with pulmonary function indices were improved,but the treatment group improved more significantly than the control group,the difference was statistically significant (P < 0.05),two groups of patients during treatment had no adverse drug reaction injury,the treatment group in the recurrence rate was lower than that in control group.Conclusion Montelukast may be used as adjuvant therapy of allergic asthma in children,and taking safety,effect is significant.